Oligopeptides

Antiviral Agents
Penetration of Atazanavir in Seminal Plasma of Men Infected with Human Immunodeficiency Virus Type 1
E. van Leeuwen, R. ter Heine, F. van der Veen, S. Repping, J. H. Beijnen, J. M. Prins
Susceptibility
In Vitro Activities of Tritrpticin Alone and in Combination with Other Antimicrobial Agents against Pseudomonas aeruginosa
Oscar Cirioni, Andrea Giacometti, Carmela Silvestri, Agnese Della Vittoria, Alberto Licci, Alessandra Riva, Giorgio Scalise
Pharmacology
Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection
Sara Colombo, Thierry Buclin, Matthias Cavassini, Laurent A. Décosterd, Amalio Telenti, Jérôme Biollaz, Chantal Csajka
Mechanisms of Action: Physiological Effects
Studies on the Mode of Action of the Antifungal Hexapeptide PAF26
Alberto Muñoz, Belén López-García, Jose F. Marcos
Pharmacology
Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers
D. M. Burger, S. Agarwala, M. Child, A. Been-Tiktak, Y. Wang, R. Bertz
Antiviral Agents
VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
Kai Lin, Robert B. Perni, Ann D. Kwong, Chao Lin
Antiviral Agents
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
Robert B. Perni, Susan J. Almquist, Randal A. Byrn, Gurudatt Chandorkar, Pravin R. Chaturvedi, Lawrence F. Courtney, Caroline J. Decker, Kirk Dinehart, Cynthia A. Gates, Scott L. Harbeson, Angela Heiser, Gururaj Kalkeri, Elaine Kolaczkowski, Kai Lin, Yu-Ping Luong, B. Govinda Rao, William P. Taylor, John A. Thomson, Roger D. Tung, Yunyi Wei, Ann D. Kwong, Chao Lin
Antiviral Agents
Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones
S. Weinheimer, L. Discotto, J. Friborg, H. Yang, R. Colonno
Antiviral Agents
Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors
Joseph Yanchunas, David R. Langley, Li Tao, Ronald E. Rose, Jacques Friborg, Richard J. Colonno, Michael L. Doyle
Antiviral Agents
Orally Active Antiviral Tripeptide Glycyl-Prolyl-Glycinamide Is Activated by CD26 (Dipeptidyl Peptidase IV) before Transport across the Intestinal Epithelium
Ina Hubatsch, Lucia Lazorova, Anders Vahlne, Per Artursson

Main menu

User menu

Search

Oligopeptides

Pages